抑那通治疗前列腺癌的最新进展-expertppt参考课件.pptVIP

AUA(2010)内分泌治疗新进展 Sarcopenia in men receiving androgen deprivation therapy for prostate cancer: a prospective 3-year study. Matthew R. Smith,CA. AUA(2010)内分泌治疗新进展 INTRODUCTION AND OBJECTIVES Androgen deprivation therapy (ADT) for prostate cancer decreases bone mineral density and increases fracture risk. Studies with limited sample size and observational periods have reported that ADT is also associated with sarcopenia or loss of muscle (lean body mass, LBM). We now report the prospective changes in LBM in a subset of men from that study. AUA(2010)内分泌治疗新进展 METHODS Men undergoing ADT for nonmetastatic prostate cancer at 38 centers in North America were randomized to denosumab or placebo. A total of 248 subjects (130 denosumab, 118 placebo) with a baseline and with at least 1 on-study LBM result were considered evaluable and included in this analysis. AUA(2010)内分泌治疗新进展 METHODS Subjects were stratified at baseline by age (70 years vs ≥70 years) and by duration of ADT treatment (≤6 months vs 6 months). LBM was measured by total body dual-energy x-ray absorptiometry at baseline and at 12, 24, and 36 months. AUA(2010)内分泌治疗新进展 RESULTS From baseline to month 12, mean LBM decreased significantly by 1.0% (p=.0004). Significant decreases in LBM were also observed at month 24 (2.1%, p.0001) and month 36 (2.4%, p.0001). AUA(2010)内分泌治疗新进展 RESULTS Men aged ≥70 years(n=127) had significantly greater changes in LBM at all measured time points. At 36 months, LBM decreased by 2.8% in men aged ≥70 years compared with a decrease of 0.9% in younger men (p=0.035). AUA(2010)内分泌治疗新进展 CONCLUSION This is the largest and longest prospective study undertaken to describe the natural history of muscle loss in men undergoing ADT therapy for prostate cancer. LBM significantly decreased at 12, 24, and 36 months. Decreases in LBM were greatest in older men and in those who had short duration of ADT at study entry. AUA(2010)内分泌治疗新进展 Recovery of testosterone and PSA after ce